PMID- 12163121
OWN - NLM
STAT- MEDLINE
DCOM- 20030320
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 449
IP  - 1-2
DP  - 2002 Aug 2
TI  - Amelioration by beraprost sodium, a prostacyclin analogue, of established renal 
      dysfunction in rat glomerulonephritis model.
PG  - 167-76
AB  - Effects of beraprost sodium, a chemically stable prostacyclin analogue, on renal 
      dysfunction in an experimental rat model of glomerulonephritis were investigated. 
      Beraprost sodium (30, 100 and 300 microg/kg) was orally given twice daily from 
      the late stage of nephritis in which renal dysfunction was already developed. 
      Beraprost sodium treatment inhibited the increase in urinary protein, serum 
      creatinine and blood urea nitrogen, and the decrease in creatinine clearance. The 
      elevation of serum creatinine was also inhibited by predonisolone (1 mg/kg). 
      However, captopril (25, 50 and 100 mg/kg) and dipyridamole (20 and 60 mg/kg) 
      failed to inhibit the elevation of serum creatinine. In the beraprost 
      sodium-treated nephritic rats, the increase in mRNA levels for monocyte 
      chemoattractant protein-1 (MCP-1) and collagen in the kidney was inhibited. These 
      results suggest that beraprost sodium ameliorates developed renal dysfunction and 
      is possibly an effective agent for the treatment of human glomerulonephritis.
FAU - Yamada, Masateru
AU  - Yamada M
AD  - Pharmaceutical Research Laboratories, Toray Industries, Inc., 1111 Tebiro 
      Kamakura, Kanagawa 248-8555, Japan.
FAU - Sasaki, Rie
AU  - Sasaki R
FAU - Sato, Nahoko
AU  - Sato N
FAU - Suzuki, Motohiro
AU  - Suzuki M
FAU - Tamura, Mitsutaka
AU  - Tamura M
FAU - Matsushita, Teruo
AU  - Matsushita T
FAU - Kurumatani, Hajimu
AU  - Kurumatani H
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (RNA, Messenger)
RN  - 35E3NJJ4O6 (beraprost)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9G64RSX1XD (Captopril)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - AYI8EX34EU (Creatinine)
RN  - DCR9Z582X0 (Epoprostenol)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Animals
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Blood Urea Nitrogen
MH  - Body Weight/drug effects
MH  - Captopril/therapeutic use
MH  - Chemokine CCL2/biosynthesis/metabolism
MH  - Creatinine/urine
MH  - Dipyridamole/therapeutic use
MH  - Epoprostenol/*analogs & derivatives/*therapeutic use
MH  - Glomerulonephritis/*drug therapy/physiopathology
MH  - Kidney/drug effects/metabolism/*physiopathology
MH  - Kidney Function Tests
MH  - Kidney Glomerulus/immunology
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prednisolone/therapeutic use
MH  - Proteinuria/chemically induced
MH  - RNA, Messenger/biosynthesis
MH  - Rabbits
MH  - Rats
MH  - Rats, Inbred WKY
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2002/08/07 10:00
MHDA- 2003/03/21 04:00
CRDT- 2002/08/07 10:00
PHST- 2002/08/07 10:00 [pubmed]
PHST- 2003/03/21 04:00 [medline]
PHST- 2002/08/07 10:00 [entrez]
AID - S001429990201988X [pii]
AID - 10.1016/s0014-2999(02)01988-x [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2002 Aug 2;449(1-2):167-76. doi: 10.1016/s0014-2999(02)01988-x.